TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Nyxoah Sa
Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule

Nyxoah announced CMS has increased Medicare reimbursement for its Genio hypoglossal nerve stimulation therapy by 48% for hospital outpatient departments and 58% for ambulatory surgery centers in 2026, which is expected to support broader therapy adoption.

Insights
CIFRW   positive

Company is expanding infrastructure, securing significant financing, and demonstrating strategic growth in data center and computing capabilities


NYXH   positive

Significant Medicare reimbursement increase will improve economic viability of their Genio therapy and potentially expand market access